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to 3 and the number of stages to IV. However, the database remained 
predominately based upon a surgical series from one centre in the USA.
With the retirement of Dr. Clifton Mountain the International Associa-
tion for the Study of Lung Cancer (IASLC) felt there was a need to 
continue his work and an opportunity for it, as the only global body 
to include specialists in all of the ﬁelds of diagnosis, treatment and 
research into lung cancer, to create an International database of cases 
treated by all modalities of care worldwide. With ﬁnances provided 
through a restricted educational grant by Eli Lilly and Company, data 
transfer, collection and analysis by Cancer Research And Biostatistics 
(CRAB) and the generous support of 46 databases in over 19 countries 
we have amassed data on over 100,000 cases of lung cancer treated 
between 1990 and 2000 (5). At a later stage, additional funding was 
obtained through a competitive process within the AJCC. An initial 
sift excluded those cases with inadequate data on staging or survival, 
those in which cell-type was unclear or inappropriate, those with 
recurrent disease rather than a new primary cancer and those outside 
our intended study period. There remained 81, 021 cases suitable for 
further analysis, consisting of 13,290 cases of small-cell lung cancer 
(SCLC) and 67,731 cases of non-small cell lung cancer (NSCLC). This 
data came from clinical trials, tumour registries, International registries, 
surgical registries, series treated by surgery and other modalities and 
consortia. All modalities of care were represented but understand-
ably the largest proportion were treated by surgery (41%) followed by 
chemotherapy (23%) and radiotherapy (11%), the rest being treated by 
combined modality care or best supportive care. European centres con-
tributed 58% of the NSCLC cases followed by North America (21%), 
Asia (14%) and Australia (7%). In the NSCLC cases 53,646 had data 
on clinical staging. There were 33,933 with pathological staging data 
and in 20,006 there was data on both cTNM and pTNM.
The analysis of this data was completed at the end of 2006 and the 
subsequent recommendations for the 7th edition of the TNM Classiﬁca-
tion were submitted to the UICC in December 2006. The recommenda-
tions, with supplementary suggestions regarding the TNM staging of 
SCLC and carcinoid tumours, a new concept in nodal classiﬁcation and 
comments on the role of additional prognostic factors will be submitted 
to the AJCC in June 2007. These recommendations will be published in 
the Journal of Thoracic Oncology in a series of discussion papers com-
mencing in July 2007 and will form the basis of the subsequent talks in 
this session. We have already started to prepare for the next phase of the 
project which will extend the retrospective database and create a pro-
spective database for future revisions. This will enable us to look further 
into some issues that could not be addressed in a retrospective fashion.
Our recommendations are now subject to the internal review processes 
of the UICC and AJCC, which include review by National cancer com-
mittees and an International panel of experts. Once these discussions 
are complete the 7th edition will be published in January 2009. 
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Introduction
In 1999 the International Association for the Study of Lung Cancer 
(IASLC) initiated an international staging project with the objective to 
analyse a large international database of patients with lung cancer in 
order to study the T, the N and the M components of the current lung 
cancer classiﬁcation and staging system, and eventually recommend 
revisions to the present edition (6th) of the TNM classiﬁcation. If the 
resulting changes were accepted by the Union Internationale Contre le 
Cancer (UICC) and the American Joint Committee on Cancer (AJCC), 
they would appear in the 7th edition of the TNM classiﬁcation for lung 
cancer, due to be published in 2009 (1). 
This paper is presented by the T-descriptors Subcommittee on behalf of 
the International Staging Committee, Cancer Research and Biostatis-
tics, Observers to the Committee, and Participating Institutions.
Material and method
Data on 100,869 patients were collected in the international database 
and analysed by Cancer Research and Biostatistics (CRAB). The 
T-descriptors subcommittee and CRAB analysed a subset of 18,198 
patients with non-small cell lung cancer (NSCLC) who had a complete 
set of cTNM or pTNM and sufﬁcient T-descriptor details to support the 
assigned T-stage. These included 180 patients with M1 tumours with 
additional nodule(s) in a different ipsilateral lobe from the primary 
tumour lobe. In the populations of patients with complete cTNM0 and 
pTNM0, 5,760 and 15,234, respectively, had sufﬁcient information on 
T-descriptors. Too few patients had speciﬁc information on descriptors 
of higher Ts, and most T2 descriptors (except for tumour size) and all 
T3 and T4 descriptors (except for additional nodule(s)) could not be 
analysed. The present study is focussed, therefore, on tumour size and 
additional nodule(s) in the tumour-bearing lobe or different ipsilateral 
lobe. For the speciﬁc analysis of tumour size, the population of patients 
with pT1-2N0M0 completely resected (R0) tumours was selected, but 
the identiﬁed cutpoints were also explored in the population of patients 
with any N tumours and incomplete resections. This larger popula-
tion of patients was also used to analyse the tumours with additional 
nodule(s) and their relations to T3, T4 and M1 tumours. A learning set 
of approximately 2/3 (4,891 patients) was used to develop the optimal 
size cutpoints that were then tested in the validation set of the remain-
ing 1/3 (2,589 patients). In the derivation of tumour size cutpoints, the 
running log-rank statistic produced by each hypothetical cutpoint in 
the pN0M0R0 learning set was graphed against tumour size, and the 
tumour size which coincided with the highest log-rank statistic was 
chosen as the optimal cutpoint, after rounding to the nearest whole cm. 
The results were internally validated by geographic region and type of 
database, and externally validated using the Serveillance, Epidemiol-
ogy and End Results (SEER) registry (2). 
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Results
The tumour size analysis identiﬁed four cutpoints at 2, 3, 5 and 7 cm. 
These generated ﬁve tumour size subgroups (2 cm or less; over 2 cm to 
3 cm ; over 3 cm to 5 cm ; over 5 cm to 7 cm; and over 7 cm in largest 
dimension) with statistically signiﬁcant survival differences. Five-
year survival for patients with pT1-T2N0M0R0 tumours according 
to these ﬁve tumour size subgroups was: 77%, 71%, 58%, 49%, and 
35%, respectively (p < 0.0001). The same prognostic degradation was 
found when tumours with any N and any type of resection (complete 
and incomplete) were analysed. Pathologic T2-anyN tumours greater 
than 7 cm in largest dimension were found to have similar prognosis to 
pT3-anyN tumours, with 5-year survival of 35% and 38%, respectively 
(p = 0.2739). The same degradation of survival was found when clini-
cal tumour size was analysed, but there were no statistically signiﬁcant 
differences in the ﬁrst three smaller size groups. Clinical T2N0 tumours 
greater than 7 cm and cT3N0 tumours had similar prognosis, too, with 
5-year survival rates of 26% and 29%, respectively (p = 0.6111). 
Pathologic T4N0-anyR tumours so classiﬁed by the presence of ad-
ditional nodule(s) in the same lobe had the same prognosis as pT3N0-
anyR tumours, with 5-year survival rates of 45% and 38%, respectively 
(p = 0.3685). 
Pathologic M1 (N0 R0) tumours so classiﬁed by additional nodule(s) in 
another ipsilateral lobe had similar prognosis to pT4 tumours by other 
descriptors other than additional nodule(s). Their 5-year survival rates 
were 48% and 35%, respectively (p = 0.1090).
Patients with cT4N0 tumours by pleural dissemination (pleural effusion 
or pleural nodules) had signiﬁcantly worse prognosis than patients with 
cT4N0 tumours by other descriptors. Five-year survival rates were 2% 
and 25%, respectively (p = 0.0001). Survival of patients with cT4N0 
tumours by pleural dissemination was similar to that of patients with 
M1 tumours.
All these results were internally and externally validated.
Conclusions
Based on the results of this study, the following changes in the next edi-
tion of the TNM classiﬁcation for lung cancer can be recommended: 
1) T1 tumours could be subclassiﬁed as T1a (2 cm or less) or T1b (over 
2 cm to 3 cm); 
2) T2 tumours could be subclassiﬁed as T2a (over 3 cm to 5 cm, or T2 
by other descriptor and 5 cm or less in largest dimension) or T2b 
(over 5 cm to 7 cm); 
3) T2 tumours over 7 cm in largest dimension could be reclassiﬁed as 
T3; 
4) T4 tumours by additional nodule(s) in the same lobe could be reclas-
siﬁed as T3; 
5) M1 tumours by additional nodule(s) in a different ipsilateral lobe 
could be reclassiﬁed as T4; and 
6) pleural dissemination (malignant pleural and pericardial effusions 
and pleural nodules) could be reclassiﬁed as M1. 
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Accurate staging of lymph node involvement is a critical aspect of 
the initial management of patients with non-metastatic non-small cell 
lung cancer (NSCLC) that inﬂuences decisions about the appropriate-
ness and timing of surgery, radiation and systemic therapy. Since the 
lung cancer staging system was ﬁrst developed in 19731, lymph node 
involvement has been categorized as N0 (no nodes involved), N1 
(peribronchial, interlobar or perihiar lymph nodes involved) N2 (ipsi-
lateral mediastinal nodes involved), or N3 (contralateral mediastinal or 
supraclavicular nodes involved). 
During the past 20 years, numerous studies have evaluated the validity 
of the N descriptors and have suggested that these could be reﬁned to 
provide more accurate prognostic stratiﬁcation by subdividing them 
either according to speciﬁc anatomical locations (e.g. N1 peribronchial 
versus N1 perihilar) or the number of involved lymph nodes (e.g. single 
versus multiple N2 nodes). This study was undertaken as part of the 
effort by the staging committee of the International Association for the 
Study of Lung Cancer (IASLC) to determine if the current international 
lung cancer staging system required revision in preparation for the 7th 
edition of the UICC (Union Internationale Contre le Cancer) and AJCC 
(American Joint Commission on Cancer) cancer staging manuals.
The database was developed through an international consortium 
of institutions and clinical trials groups that submitted staging and 
outcome data on a total of 100,869 lung cancer cases managed within 
the time frame of 1990-2000. Of the 67,725 NSCLC that met the initial 
screening requirements of a complete set of TNM by either clinical or 
pathological staging, known histological type, and survival follow-up, 
38,265 cases with no clinical evidence of metastatic disease (cM0) had 
information on clinical N staging (cN) and 28,371 surgically managed 
patients provided information on pathologic N staging (pN). Further 
analyses of overall survival in relationship to subsets of pN1 and pN2 
stages were performed on 2,876 cases that underwent R0 (microscopi-
cally complete) resection without induction therapy and that success-
fully met logic checks of pN stage for data accuracy.
Surgical cases form Japan were staged according to the Naruke lymph 
node map, adopted by the Japan Lung Cancer Society as the ofﬁcial 
staging map2, while those from all other countries were staged accord-
ing to the Mountain-Dresler modiﬁcation of the American Thoracic 
society (MD-ATS) map.3 Survival was measured from the date of entry 
(date of diagnosis for registries, date of registration for protocols) for 
clinically staged data and the date of surgery for pathologically staged 
data, and was calculated by the Kaplan-Meier method. Prognostic 
groups were assessed by Cox regression analysis.
The overall survival by cN staging for all 38,265 cM0 (any T stage) 
showed clear differences in outcome for each of the cN categories. 
The overall survival by pN staging for the 28,371 cM0 (any T stage) 
patients who were managed surgically (and also had no evidence of in-
trathoracic M1 disease at thoracotomy) again showed signiﬁcant differ-
ences in outcome for each of the pN categories. Exploratory analyses 
were performed to determine if, in patients with pN staging, survival 
was inﬂuenced by the anatomical location of involved lymph nodes, by 
the presence of “skip metastases” (N2 disease in the absence of N1), or 
by the number of involved lymph node stations. No signiﬁcance differ-
